Literature DB >> 32761762

CSAG2 is a cancer-specific activator of SIRT1.

Xu Yang1, Patrick Ryan Potts1.   

Abstract

SIRT1 is a NAD+ -dependent deacetylase that controls key metabolic and signaling pathways, including inactivating the p53 tumor suppressor. However, the mechanisms controlling SIRT1 enzymatic activity in the context of cancer are unclear. Here, we show that the previously undescribed CSAG2 protein is a direct activator of SIRT1. CSAG2 is normally restricted to expression in the male germline but is frequently re-activated in cancers. CSAG2 is necessary for cancer cell proliferation and promotes tumorigenesis in vivo. Biochemical studies revealed that CSAG2 directly binds to and stimulates SIRT1 activity toward multiple substrates. Importantly, CSAG2 enhances SIRT1-mediated deacetylation of p53, inhibits p53 transcriptional activity, and improves cell survival in response to genotoxic stress. Mechanistically, CSAG2 binds SIRT1 catalytic domain and promotes activity independent of altering substrate affinity. Together, our results identify a previously undescribed mechanism for SIRT1 activation in cancer cells and highlight unanticipated approaches to therapeutically modulate SIRT1.
© 2020 The Authors.

Entities:  

Keywords:  NAD+-dependent deacetylase; apoptosis; cancer-testis antigen; genotoxic stress; oncogene

Mesh:

Substances:

Year:  2020        PMID: 32761762      PMCID: PMC7507327          DOI: 10.15252/embr.202050912

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  53 in total

1.  SIRT1 contains N- and C-terminal regions that potentiate deacetylase activity.

Authors:  Min Pan; Hua Yuan; Michael Brent; Emily Chen Ding; Ronen Marmorstein
Journal:  J Biol Chem       Date:  2011-12-07       Impact factor: 5.157

Review 2.  SIRT1 and p53, effect on cancer, senescence and beyond.

Authors:  Jingjie Yi; Jianyuan Luo
Journal:  Biochim Biophys Acta       Date:  2010-05-13

3.  The Roles of SIRT1 in Cancer.

Authors:  Zhenghong Lin; Deyu Fang
Journal:  Genes Cancer       Date:  2013-03

4.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.

Authors:  Mario F Fraga; Esteban Ballestar; Ana Villar-Garea; Manuel Boix-Chornet; Jesus Espada; Gunnar Schotta; Tiziana Bonaldi; Claire Haydon; Santiago Ropero; Kevin Petrie; N Gopalakrishna Iyer; Alberto Pérez-Rosado; Enrique Calvo; Juan A Lopez; Amparo Cano; Maria J Calasanz; Dolors Colomer; Miguel Angel Piris; Natalie Ahn; Axel Imhof; Carlos Caldas; Thomas Jenuwein; Manel Esteller
Journal:  Nat Genet       Date:  2005-03-13       Impact factor: 38.330

Review 5.  Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer.

Authors:  Yolanda Olmos; Jan J Brosens; Eric W-F Lam
Journal:  Drug Resist Updat       Date:  2010-12-30       Impact factor: 18.500

6.  Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase.

Authors:  S Imai; C M Armstrong; M Kaeberlein; L Guarente
Journal:  Nature       Date:  2000-02-17       Impact factor: 49.962

7.  Sirtuin deacetylases: a new target for melanoma management.

Authors:  Melissa J Wilking; Chandra K Singh; Minakshi Nihal; Mary A Ndiaye; Nihal Ahmad
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

8.  Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice.

Authors:  Hwei-Ling Cheng; Raul Mostoslavsky; Shin'ichi Saito; John P Manis; Yansong Gu; Parin Patel; Roderick Bronson; Ettore Appella; Frederick W Alt; Katrin F Chua
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

9.  Negative regulation of the deacetylase SIRT1 by DBC1.

Authors:  Wenhui Zhao; Jan-Philipp Kruse; Yi Tang; Sung Yun Jung; Jun Qin; Wei Gu
Journal:  Nature       Date:  2008-01-31       Impact factor: 49.962

10.  Crystallographic structure of a small molecule SIRT1 activator-enzyme complex.

Authors:  Han Dai; April W Case; Thomas V Riera; Thomas Considine; Jessica E Lee; Yoshitomo Hamuro; Huizhen Zhao; Yong Jiang; Sharon M Sweitzer; Beth Pietrak; Benjamin Schwartz; Charles A Blum; Jeremy S Disch; Richard Caldwell; Bruce Szczepankiewicz; Christopher Oalmann; Pui Yee Ng; Brian H White; Rebecca Casaubon; Radha Narayan; Karsten Koppetsch; Francis Bourbonais; Bo Wu; Junfeng Wang; Dongming Qian; Fan Jiang; Cheney Mao; Minghui Wang; Erding Hu; Joe C Wu; Robert B Perni; George P Vlasuk; James L Ellis
Journal:  Nat Commun       Date:  2015-07-02       Impact factor: 14.919

View more
  3 in total

Review 1.  Role and Clinical Utility of Cancer/Testis Antigens in Head and Neck Squamous Cell Carcinoma.

Authors:  Sharon Changshan Wu; Karl Münger
Journal:  Cancers (Basel)       Date:  2021-11-14       Impact factor: 6.639

2.  CSAG2 is a cancer-specific activator of SIRT1.

Authors:  Xu Yang; Patrick Ryan Potts
Journal:  EMBO Rep       Date:  2020-08-05       Impact factor: 8.807

Review 3.  RNA-binding proteins in ovarian cancer: a novel avenue of their roles in diagnosis and treatment.

Authors:  Jiangchun Wu; Yong Wu; Qinhao Guo; Simin Wang; Xiaohua Wu
Journal:  J Transl Med       Date:  2022-01-21       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.